NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Shares of Vertex Pharmaceuticals Inc. VRTX rallied 2.53% to $482.28 Tuesday, on what proved to be an all-around great trading ...

This was the stock's second consecutive day of gains.

Missouri woman with autism has a request for the Chiefs: she wants to be the team’s water girl Ye shocked at the Grammys red ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

Allstate HBCU Legacy BowlSC State's Chennis Berry to co-head coach TEAM GAITHER at the legacy bowl featuring MEAC and CIAA ...

The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.

The initial concept to focus on pain-signaling proteins came out of research involving people with a rare hereditary ...

It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and overdose associated with opioids.